Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701394 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13293933 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523784 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523768 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL10032114 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13293936 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523782 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13602667 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523767 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13293934 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2016-02-25 | — | — | US | disclosed |
| US-9217015-B2 | Cyclosporin derivatives for the treatment and prevention of a viral infection | S&T GLOBAL INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150111815-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | S & T GLOBAL INC (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2013-11-14 | — | — | US | disclosed |
| US-7728150-B2 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | MARTINEZ-PEREZ JOSE ANTONIO | 2010-04-15 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-08-09 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7247644-B2 | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics | ELI LILLY AND COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070088016-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7157582-B2 | Selective iGluR5 receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | HRH3 3637/4885CXCR4 465/4885SIGMAR1 2898/4885 |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | HRH3 4818/4885CXCR4 3546/4885SIGMAR1 2494/4885 |
| US-20150111815-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HAVCR2, TSLP, HLA-DRB1 | HRH3 3834/4885CXCR4 654/4885SIGMAR1 3056/4885 |
| US-20100094014-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, GRIN1 | HRH3 467/4885CXCR4 2505/4885SIGMAR1 323/4885 |
| US-20070185161-A1 | Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR1H2 | HRH3 536/4885CXCR4 394/4885SIGMAR1 276/4885 |
| US-20070088016-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR3C2, NR3C1, NR5A1 | HRH3 565/4885CXCR4 788/4885SIGMAR1 332/4885 |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | HRH3 3637/4885CXCR4 465/4885SIGMAR1 2898/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | HRH3 2934/4885CXCR4 1479/4885SIGMAR1 1229/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | HRH3 1043/4885CXCR4 1406/4885SIGMAR1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.